Back to top

oncology-screening: Archive

Zacks Equity Research

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

AZNPositive Net Change MRNANegative Net Change IMTXNegative Net Change ABSINegative Net Change